Covered recipient · General Payments record
ROHAN GARJE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$10,277.21
15 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,150.00 | 2 |
| Food and Beverage | $712.55 | 12 |
| Travel and Lodging | $414.66 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $9,925.90 | 10 |
| PFIZER INC. | $172.79 | 2 |
| Exelixis Inc. | $133.64 | 1 |
| Blue Earth Diagnostics | $23.93 | 1 |
| Merck Sharp & Dohme LLC | $20.95 | 1 |
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROHAN GARJE
NPI 1184902884 · CMS profile ID 9005
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROHAN GARJE, NPI 1184902884, CMS profile ID 9005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ROHAN GARJE, NPI 1184902884, CMS profile ID 9005. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ROHAN GARJE, NPI 1184902884, CMS profile ID 9005, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–15 of 15 matching records. This page contains 15 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1184902884?year=2025&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
15 matching records · $10,277.21 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–15 of 15.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $6,700.00 | 10/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265232 | CMS |
| Novartis Pharmaceuticals Corporation | $69.37 | 10/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265234 | CMS |
| Novartis Pharmaceuticals Corporation | $414.66 | 10/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207656 | CMS |
| Novartis Pharmaceuticals Corporation | $24.04 | 08/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207646 | CMS |
| Merck Sharp & Dohme LLC | $20.95 | 06/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238229306 | CMS |
| Blue Earth Diagnostics | $23.93 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1252663175 | CMS |
| Novartis Pharmaceuticals Corporation | $94.07 | 05/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207630 | CMS |
| Novartis Pharmaceuticals Corporation | $84.54 | 05/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265200 | CMS |
| Novartis Pharmaceuticals Corporation | $2,450.00 | 05/30/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200265202 | CMS |
| Novartis Pharmaceuticals Corporation | $18.29 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207632 | CMS |
| PFIZER INC. | $23.62 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229053338 | CMS |
| Exelixis Inc. | $133.64 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218802357 | CMS |
| Novartis Pharmaceuticals Corporation | $48.89 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207622 | CMS |
| PFIZER INC. | $149.17 | 02/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229113718 | CMS |
| Novartis Pharmaceuticals Corporation | $22.04 | 02/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200207624 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $220,662.04 | 21 |
| PY2024 | Principal investigator | $169,149.54 | 18 |
| PY2023 | Principal investigator | $83,135.64 | 3 |
| PY2022 | Principal investigator | $197,817.83 | 17 |
| PY2021 | Principal investigator | $171,207.40 | 2 |
| PY2020 | Principal investigator | $24,741.25 | 4 |
| PY2019 | Principal investigator | $339.06 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
21 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $905.96 | 12/24/2025 | Non-covered Recipient Entity Baptist Health Medical Group Oncology Llc | A Randomized, Open-Label, Phase 2/3 Trial Of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy For Metastatic Urothelial Cancer In Participants With Disease Progresssion On Or After An Immunotherapy-Based Treatment | No dispute reported | 06/30/2026 | 1235998794 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,527.12 | 12/16/2025 | Non-covered Recipient Entity Miami Cancer Inst At Bapt Hlth S Fl | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175196127 |
| Principal investigator 1 | Astellas US Technologies | $98,315.00 | 12/08/2025 | Non-covered Recipient Entity Miami Cancer Institute | Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer | No dispute reported | 06/30/2026 | 1214851005 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $345.76 | 11/19/2025 | Non-covered Recipient Entity MIAMI CANCER INSTITUTE / BAPTIST H. | A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1190314103 |
| Principal investigator 1 | Astellas US Technologies | $39,326.00 | 11/18/2025 | Non-covered Recipient Entity Miami Cancer Institute | Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer | No dispute reported | 06/30/2026 | 1214851009 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 11/07/2025 | Non-covered Recipient Entity Miami Cancer Inst At Bapt Hlth S Fl | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175194359 |
| Principal investigator 1 | Astellas US Technologies | $58,989.00 | 10/29/2025 | Non-covered Recipient Entity Miami Cancer Institute | Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer | No dispute reported | 06/30/2026 | 1214851016 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,858.00 | 09/05/2025 | Non-covered Recipient Entity Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175195169 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 08/22/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379654 |
| Principal investigator 1 | Exelixis Inc. | $750.00 | 08/22/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379658 |
| Principal investigator 1 | Exelixis Inc. | $400.00 | 08/22/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379660 |
| Principal investigator 1 | Exelixis Inc. | $1,000.00 | 08/22/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379662 |
| Principal investigator 1 | Exelixis Inc. | $800.00 | 08/18/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 07/23/2025 | Non-covered Recipient Entity Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175196391 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,858.00 | 07/14/2025 | Non-covered Recipient Entity Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175195492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 07/01/2025 | Non-covered Recipient Entity Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175194750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 06/09/2025 | Non-covered Recipient Entity Bapt Hlth Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175196202 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,802.60 | 04/28/2025 | Non-covered Recipient Entity Bapt Hlth Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175197301 |
| Principal investigator 1 | Genentech, Inc. | $4,000.00 | 04/08/2025 | Non-covered Recipient Entity MIAMI CANCER INSTITUTE AT BAPTIST HEALTH INC | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | No dispute reported | 06/30/2026 | 1211625207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,802.60 | 04/04/2025 | Non-covered Recipient Entity Bapt Hlth Miami Cancer Inst | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175196624 |
| Principal investigator 1 | Exelixis Inc. | $800.00 | 01/08/2025 | Non-covered Recipient Entity Baptist Health South Florida, Inc | A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors. | No dispute reported | 06/30/2026 | 1222379652 |